Brown & Brown
BRO
$60.15
-2.42%
Brown & Brown, Inc. is a diversified insurance agency and wholesale brokerage firm operating within the Financial Services sector, specifically the Insurance Brokers industry. The company is a significant player in the market, distinguished by its dual-segment model encompassing Retail insurance services and Specialty Distribution, which includes wholesale brokerage and specialty programs. The current investor narrative is heavily focused on the company's aggressive acquisition strategy to drive growth, as evidenced by recent deals like the purchase of The Protectorate Group, while simultaneously navigating a challenging market environment that has led to a significant stock price decline and raised questions about valuation and future organic growth prospects.…
BRO
Brown & Brown
$60.15
Related headlines
BRO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Brown & Brown's 12-month outlook, with a consensus price target around $78.20 and implied upside of +30.0% versus the current price.
Average Target
$78.20
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$48 - $78
Analyst target range
Analyst coverage for BRO is limited, with only 6 analysts providing estimates, indicating this is a mid-cap stock with less institutional scrutiny which can contribute to higher volatility. The available data shows analyst estimates for future EPS averaging $5.43, with a tight range from $5.37 to $5.49, suggesting strong consensus on near-term profitability. The institutional ratings data reveals a predominantly neutral to cautious stance, with recent actions including a downgrade from Citigroup (from Buy to Neutral) and an upgrade from Mizuho (from Neutral to Outperform), while firms like Barclays, Wells Fargo, Morgan Stanley, and UBS maintain Equal Weight or Neutral ratings. This mixed but generally non-bullish sentiment, combined with the stock's steep price decline, creates a contrarian setup where the stock's performance is highly dependent on the company exceeding the market's subdued expectations.
Bulls vs Bears: BRO Investment Factors
The evidence currently tilts bearish, given the stock's catastrophic relative underperformance, valuation de-rating, and cautious analyst stance, which collectively outweigh its strong fundamental profitability and cash flow. The bull case rests on the deep valuation discount and oversold technicals providing a margin of safety, while the bear case emphasizes a broken growth narrative and persistent selling pressure. The single most important tension in the investment debate is whether the company's aggressive acquisition strategy can successfully transition to generating sustainable organic growth and earnings that justify its forward multiple, or if the market's skepticism about acquisition-led growth proves correct, leading to further multiple compression.
Bullish
- Strong Revenue Growth & Profitability: Q4 2025 revenue grew 53.3% year-over-year to $1.67 billion, driven by acquisitions. The company maintains robust profitability with a trailing net margin of 17.7% and an exceptionally high gross margin of 87.7%, which is characteristic of its asset-light brokerage model.
- Significant Free Cash Flow Generation: The company generated $1.43 billion in trailing twelve-month free cash flow, providing ample liquidity for strategic acquisitions, debt repayment, and shareholder returns. This strong cash generation underpins the sustainability of its growth strategy.
- Attractive Forward Valuation: The stock trades at a forward P/E of 13.25x based on analyst EPS estimates of $5.43, representing a significant discount to its trailing P/E of 23.44x. This implies the market expects earnings growth and suggests potential for multiple expansion if targets are met.
- Oversold Technical Condition: The stock is down 44.0% over the past year and trades just 4.1% above its 52-week low of $63.29, having experienced a maximum drawdown of -49.0%. This deep oversold condition, with a beta of 0.83 indicating less volatility than the market, may present a contrarian entry point if fundamentals stabilize.
Bearish
- Severe Price & Relative Underperformance: The stock has dramatically underperformed the market, with a 1-year relative strength of -74.6% versus the SPY. A 6-month decline of -25.1% and a drop of 43.4% from its 52-week high signal deep investor skepticism and a broken technical trend.
- Valuation Compression & Growth Concerns: The trailing P/E has compressed from 34.19x in Q3 2025 to 23.44x currently, indicating the market is de-rating the stock despite earnings growth. This suggests concerns over the sustainability of acquisition-driven growth and future organic expansion.
- Mixed-to-Neutral Analyst Sentiment: With only 6 analysts covering the stock, recent actions include a downgrade from Citigroup (Buy to Neutral) and an upgrade from Mizuho (Neutral to Outperform). The prevailing Equal Weight/Neutral ratings reflect caution and a lack of strong bullish conviction.
- Potential Earnings Quality & Integration Risk: The massive 53.3% YoY revenue growth is heavily acquisition-fueled, raising questions about the quality and sustainability of earnings. The company faces execution risk in integrating acquisitions and achieving promised synergies to justify its purchase premiums.
BRO Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -44.04% and a 6-month decline of -25.11%. Trading at a current price of $65.90, it sits just 4.1% above its 52-week low of $63.29 and a substantial 43.4% below its 52-week high of $116.41, positioning it deeply in oversold territory and suggesting either a deep value opportunity or a stock facing severe fundamental headwinds. Recent momentum shows a slight 1-month gain of 2.50%, which diverges positively from the longer-term downtrend, but this is juxtaposed against a sharp 3-month loss of -16.77%, indicating any recent stabilization is fragile and occurring from a very depressed base. The stock's beta of 0.826 suggests it has been less volatile than the broader market during this sell-off, but its severe relative underperformance is stark, with a 1-year relative strength of -74.63% versus the SPY. Key technical support is firmly established at the 52-week low near $63.29, while resistance begins at the recent local highs around the $73-$74 area from early March; a decisive break below support could trigger another leg down, whereas a sustained move above $74 might signal the beginning of a basing process.
Beta
0.83
0.83x market volatility
Max Drawdown
-51.7%
Largest decline past year
52-Week Range
$59-$114
Price range past year
Annual Return
-45.6%
Cumulative gain past year
| Period | BRO Return | S&P 500 |
|---|---|---|
| 1m | -7.8% | +10.5% |
| 3m | -16.6% | +3.9% |
| 6m | -24.6% | +5.4% |
| 1y | -45.6% | +29.6% |
| ytd | -22.5% | +5.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRO Fundamental Analysis
Revenue growth has been robust on a year-over-year basis, with Q4 2025 revenue of $1.669 billion representing a 53.26% increase from the prior year's quarter, though this surge is likely heavily influenced by acquisitions. Sequentially, revenue has grown from $1.249 billion in Q2 to $1.606 billion in Q3 to the current $1.669 billion, indicating a steady upward trajectory. The company is solidly profitable, reporting Q4 net income of $264 million and a trailing net margin of 17.70%, supported by a very high gross margin of 87.68% which is characteristic of the insurance brokerage business model. Profitability metrics are healthy, with a Return on Equity of 8.40% and a Return on Assets of 4.24%, though these levels are moderate and reflect the capital-intensive nature of the industry. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.63, and the company generates substantial cash, with trailing twelve-month free cash flow of $1.43 billion, providing ample liquidity for further acquisitions and shareholder returns while maintaining a current ratio of 1.04.
Quarterly Revenue
$1.7B
2025-12
Revenue YoY Growth
+0.53%
YoY Comparison
Gross Margin
+0.83%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRO Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 23.44x, which is notably higher than the forward P/E of 13.25x, implying the market expects significant earnings growth in the coming year to justify the current price. Compared to its own historical valuation, the current trailing P/E of 23.44x is below the multi-year highs seen in recent quarters (e.g., 34.19x in Q3 2025) but remains above the lows observed in early 2023 (around 15.77x), placing it in the mid-to-lower range of its recent historical band. This compression from higher multiples suggests the market has de-rated the stock due to growth concerns or sector-wide pressures, even as earnings have grown. The forward P/E discount to the trailing multiple indicates embedded expectations for earnings acceleration, which will need to be realized through successful integration of acquisitions and organic growth to support the valuation.
PE
23.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~48x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the dependence on acquisitions for growth, as evidenced by the 53.3% YoY revenue surge in Q4 2025, which may mask weakening organic trends. While the balance sheet shows moderate leverage (Debt/Equity of 0.63) and strong liquidity (Current Ratio of 1.04), the company must continue generating substantial free cash flow ($1.43B TTM) to fund its M&A strategy without over-leveraging. Earnings volatility is a concern, as net margin has fluctuated quarterly, and the forward P/E of 13.25x embeds high expectations for earnings growth that may not materialize if integration costs rise or synergies disappoint.
Market & Competitive Risks: The stock faces significant valuation compression risk, having traded as high as 34.19x trailing P/E in Q3 2025 before falling to 23.44x. If sector-wide de-rating continues or growth decelerates, the forward multiple could contract further. Competitive pressures in the insurance brokerage industry are intense, and BRO's model relies on continual consolidation. The stock's beta of 0.83 suggests it is less volatile than the market, but its severe underperformance indicates company-specific or sector-specific headwinds that may persist, such as concerns over insurance premium cycles or economic sensitivity impacting client spending.
Worst-Case Scenario: The worst-case scenario involves a failure to integrate recent acquisitions profitably, leading to an earnings miss, a halt in the M&A engine due to financing constraints or overpaying, and a subsequent loss of investor confidence. This could trigger a re-rating to the lower end of its historical P/E range (near 15x) on reduced earnings estimates. Quantitatively, the stock could revisit and break below its 52-week low of $63.29, representing a -4.1% decline from the current $65.90. A more severe bear case, aligning with the maximum drawdown of -49.0%, suggests a potential fall to the mid-$50s, implying a downside risk of -15% to -20% from current levels.